Outcomes and risks in palliative pancreatic surgery

• Verfasst von: Hofmann, Felix O. [VerfasserIn]
• Verfasst von: Miksch, Rainer C. [VerfasserIn]
• Verfasst von: Weniger, Maximilian [VerfasserIn]
• Verfasst von: Keck, Tobias [VerfasserIn]
• Verfasst von: Anthuber, Matthias [VerfasserIn]
• Verfasst von: Witzigmann, Helmut [VerfasserIn]
• Verfasst von: Nuessler, Natascha C. [VerfasserIn]
• Verfasst von: Reißfelder, Christoph [VerfasserIn]
• Verfasst von: Köninger, Jörg [VerfasserIn]
• Verfasst von: Ghadimi, Michael [VerfasserIn]
• Verfasst von: Bartsch, Detlef K. [VerfasserIn]
• Verfasst von: Hartwig, Werner [VerfasserIn]
• Verfasst von: Angele, Martin K. [VerfasserIn]
• Verfasst von: D’Haese, Jan G. [VerfasserIn]
• Verfasst von: Werner, Jens [VerfasserIn]
• Titel: Outcomes and risks in palliative pancreatic surgery
• Titelzusatz: an analysis of the German StuDoQ|Pancreas registry
• Verf.angabe: Felix O. Hofmann, Rainer C. Miksch, Maximilian Weniger, Tobias Keck, Matthias Anthuber, Helmut Witzigmann, Natascha C. Nuessler, Christoph Reissfelder, Jörg Köninger, Michael Ghadimi, Detlef K. Bartsch, Werner Hartwig, Martin K. Angele, Jan G. D’Haese and Jens Werner
• E-Jahr: 2022
• Jahr: 11 November 2022
• Umfang: 11 S.
• Fussnoten: Gesehen am 17.07.2023
• Titel Quelle: Enthalten in: BMC surgery
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2022
• Band/Heft Quelle: 22(2022), Artikel-ID 389, Seite 1-11
• ISSN Quelle: 1471-2482
• DOI: doi:10.1186/s12893-022-01833-3
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1852774185

Abstract

Non-resectability is common in patients with pancreatic ductal adenocarcinoma (PDAC) due to local invasion or distant metastases. Then, biliary or gastroenteric bypasses or both are often established despite associated morbidity and mortality. The current study explores outcomes after palliative bypass surgery in patients with non-resectable PDAC. From the prospectively maintained German StuDoQ|Pancreas registry, all patients with histopathologically confirmed PDAC who underwent non-resective pancreatic surgery between 2013 and 2018 were retrospectively identified, and the influence of the surgical procedure on morbidity and mortality was analyzed. Of 389 included patients, 127 (32.6%) underwent explorative surgery only, and a biliary, gastroenteric or double bypass was established in 92 (23.7%), 65 (16.7%) and 105 (27.0%). After exploration only, patients had a significantly shorter stay in the intensive care unit (mean 0.5 days [SD 1.7] vs. 1.9 [3.6], 2.0 [2.8] or 2.1 [2.8]; P < 0.0001) and in the hospital (median 7 days [IQR 4-11] vs. 12 [10-18], 12 [8-19] or 12 [9-17]; P < 0.0001), and complications occurred less frequently (22/127 [17.3%] vs. 37/92 [40.2%], 29/65 [44.6%] or 48/105 [45.7%]; P < 0.0001). In multivariable logistic regression, biliary stents were associated with less major (Clavien-Dindo grade ≥ IIIa) complications (OR 0.49 [95% CI 0.25-0.96], P = 0.037), whereas—compared to exploration only—biliary, gastroenteric, and double bypass were associated with more major complications (OR 3.58 [1.48-8.64], P = 0.005; 3.50 [1.39-8.81], P = 0.008; 4.96 [2.15-11.43], P < 0.001). In patients with non-resectable PDAC, biliary, gastroenteric or double bypass surgery is associated with relevant morbidity and mortality. Although surgical palliation is indicated if interventional alternatives are inapplicable, or life expectancy is high, less invasive options should be considered.